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Abstract
Dravet syndrome (DS) is a genetically determined epileptic encephalopathy mainly caused by de novo mutations in the
SCN1A gene. Since 2003, we have performed molecular analyses in a large series of patients with DS, 27% of whom were
negative for mutations or rearrangements in SCN1A. In order to identify new genes responsible for the disorder in the
SCN1A-negative patients, 41 probands were screened for micro-rearrangements with Illumina high-density SNP microarrays.
A hemizygous deletion on chromosome Xq22.1, encompassing the PCDH19 gene, was found in one male patient. To
confirm that PCDH19 is responsible for a Dravet-like syndrome, we sequenced its coding region in 73 additional SCN1A-
negative patients. Nine different point mutations (four missense and five truncating mutations) were identified in 11
unrelated female patients. In addition, we demonstrated that the fibroblasts of our male patient were mosaic for the
PCDH19 deletion. Patients with PCDH19 and SCN1A mutations had very similar clinical features including the association of
early febrile and afebrile seizures, seizures occurring in clusters, developmental and language delays, behavioural
disturbances, and cognitive regression. There were, however, slight but constant differences in the evolution of the patients,
including fewer polymorphic seizures (in particular rare myoclonic jerks and atypical absences) in those with PCDH19
mutations. These results suggest that PCDH19 plays a major role in epileptic encephalopathies, with a clinical spectrum
overlapping that of DS. This disorder mainly affects females. The identification of an affected mosaic male strongly supports
the hypothesis that cellular interference is the pathogenic mechanism.
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Introduction
Epileptic encephalopathies are a group of rare disorders in
which impairment of cognitive, behavioural and other brain
functions is caused by the same underlying disease process. This
heterogeneous group of disorders has multiple aetiologies such as
symptomatic brain lesions, metabolic causes and diverse genetic
syndromes. Much progress has been made in the past few years in
the identification of genes responsible for genetic infantile epileptic
encephalopathies. Among the genetic syndromes that have been
characterized are: Dravet syndrome (DS), also called severe
myoclonic epilepsy of infancy (SMEI, MIM# 607208) [1],
CDKL5/STK9 Rett-like epileptic encephalopathy [2,3], ARX-
related epileptic encephalopathies [4], SRPX2-related rolandic
epilepsy associated with oral and speech dyspraxia and mental
retardation [5], and very recently, female-limited epilepsy and
cognitive impairment (EFMR) associated with mutations in
PCDH19, the gene encoding the protocadherin 19 on the X
chromosome [6].
Dravet syndrome is characterized by the occurrence of
generalized or unilateral clonic or tonic–clonic seizures, usually
triggered by fever, in the first year of life of a previously normal
infant. Later on, other types of seizures occur, including
myoclonus, atypical absences and partial seizures [7]. Develop-
PLoS Genetics | www.plosgenetics.org 1 February 2009 | Volume 5 | Issue 2 | e1000381ment is progressively delayed starting from the second year.
Susceptibility to febrile seizures persists over time, and status
epilepticus is frequent. Epilepsy generally persists despite appropri-
ate anti-epileptic therapy (polytherapy including sodium valproate,
clobazam or topiramate and stiripentol). Children with DS
typically have poorly developed language and motor skills,
learning disabilities and variable degrees of mental retardation
[8]. They are usually sporadic cases; however, sib pairs with
SMEI, or patients with a family history of epilepsy, have
occasionally been reported [9].
Heterozygous de novo mutations in SCN1A, the gene encoding
the voltage-gated neuronal sodium channel alpha 1 subunit
(Nav1.1), are a major cause of DS [1]. All types of mutations [10]
and rearrangements [11–15] in SCN1A have been observed in
SMEI patients. However, no point mutations or rearrangements
have been found in a fraction of patients, now estimated to 20–
25% [15–18], strongly suggesting that DS is a genetically
heterogeneous disorder.
Our aim was to identify the gene(s) involved in SCN1A-negative
patients with Dravet syndrome. Most of our patients were isolated,
excluding the use of classical genetic approaches. Our hypothesis
was that genomic micro-rearrangements, which are increasingly
identified as causes of human genetic disorders, might be found in
a subset of the SCN1A-negative patients with DS, thus identifying
new causal genes.
In this study, we have searched for genomic rearrangements in
41 SCN1A-negative patients using high-density SNP microarrays
(Illumina, 370K). Genes located in the rearrangements were then
considered to be candidate genes and were analysed for point
mutations by direct sequencing in the remaining negative patients
with DS.
Results
Microarray-Based Identification of a De Novo Deletion on
Chromosome Xq22.1 Encompassing PCDH19
An initial series of 41 probands (18 females and 23 males),
referred for genetic analysis of Dravet syndrome but negative for
point mutation and intragenic rearrangement of SCN1A [15], was
screened for genomic rearrangement using Illumina 370CNV
microarrays. A hemizygous deletion on chromosome Xq22.1 was
identified in a male patient (patient 1 from family 1). This deletion
spanned approximately 1 Mb and encompassed a single gene,
PCDH19 (Figure 1A). A duplication of the same region was
previously reported in one of 776 healthy controls (506 unrelated
healthy individuals from Northern Germany and 270 HapMap
subjects) [19], but no deletions in healthy individuals have been
recorded in the database of genomic variants. Patient 1 and his
mother were then analyzed with high-resolution CGH arrays
(Nimblegen). This analysis confirmed that the deletion spans
890 Kb, between genomic positions g.98731380 and g.99618794
on chromosome X, and showed that it has occurred de novo since
it was not found in the mother of the patient (Figure 1B).
Identification of Additional Patients with Point Mutations
in the Coding Sequence of PCDH19 by Direct Sequencing
PCDH19 encodes protocadherin 19, a transmembrane protein
of the cadherin family of calcium-dependent cell–cell adhesion
molecules, which is strongly expressed in the central nervous
system. In the postnatal brain, protocadherins might be involved
in the modulation of synaptic transmission and the generation of
specific synaptic connections [20]. PCDH19 was therefore an
attractive candidate gene for epilepsies and mental retardation. To
test whether a PCDH19 deficiency might be implicated in some
epileptic encephalopathies resembling Dravet syndrome, we
sequenced the coding region of this gene in 73 SCN1A-negative
probands (the remaining 40 patients of the initial series plus 33
additional patients, for a total of 45 females and 28 males).
Ten different variants were identified in 11 unrelated female
probands at the heterozygous state (Figure 2A). All but one were
located in exon 1: three were nonsense mutations (c.142G.T/
p.Glu48X, c.352G.T/p.Glu118X, c.859G.T/p.Glu287X), two
were small deletions and insertions creating a frameshift (c.506delC/
p.Thr169SerfsX43 and c.1036_1040dup/p.Asn347LysfsX23) and
the remaining five were missense mutations (c.361G.A/p.As-
p121Asn, c.595 G.C/p.Glu199Gln, c.1019A.G/p.Asn340Ser,
c.1628 T.C/p.Leu543Pro and c.3319 C.G/p.Arg1107Gly).
Glu48X was present in two affected sisters of family 2; Glu118X
was identified in an isolated patient (family 3) and Glu287X was
found independently in a patient with family history of epilepsy and
mental retardation (family 4) and in an isolated patient (family 5).
Interestingly, the c.3319 C.G/p.Arg1107Gly missense variant,
located in exon 6, was associated with the p.Glu287X mutation in
the proband of family 5. In family 6, cytosine 506 (c.506delC) was
deleted in a patient whose parents were unaffected, but whose female
cousin also had epilepsy and moderate mental retardation. The 5-bp
duplication (c.1036_1040dup) was present in the index case of family
7. The p.Asp121Asn mutation was identified in the index case of
family 8, who had a sister with epilepsy and psychotic disturbances.
Finally, p.Glu199Gln, p.Asn340Ser and p.Leu543Pro variants were
identified in the 4 remaining isolated patients (families 9 to 12);
Asn340Ser was found in two independent patients (families 10 and
11). These 4 missense variants (p.Asp121Asn, p.Glu199Gln,
p.Asn340Ser and p.Leu543Pro) all affected amino-acids in the
extracellular domain ofprotocadherin 19, which arehighlyconserved
in orthologs and in paralogs of PCDH19 in the delta protocadherin
family (Figure 2B). Interestingly, p.Arg1107Gly, associated with the
de novo Glu287X mutation in the proband of family 5, affected a
residue of the protein that is conserved in mammalian orthologs, but
not in other species or in paralogs (Figure 2B). To confirm that the
variants are pathogenic, we screened 180 healthy Caucasians. Only
Arg1107Gly was found in a healthy female individual and was thus
considered to be a rare polymorphism. None of the other variants was
Author Summary
Severe epilepsies associated with cognitive impairment in
children are multifarious and most affected patients are
sporadic cases. Thus, there is a challenge to identify which
of these epilepsies are genetically determined, since their
sporadic status excludes the use of classical genetic
approaches. We have used microarrays, which are new
technological tools to investigate the whole genome of an
individual, to search for small genomic abnormalities and
identify novel genes in 41 patients with a clinically well-
characterized severe infantile epileptic disorder called
Dravet syndrome. We have identified PCDH19, a new gene
on chromosome X, which was recently found in a familial
epileptic syndrome known as female-limited epilepsy and
cognitive impairment. This gene was mutated in 12 out of
74 patients with clinical features compatible with Dravet
syndrome. Eleven of these patients were females. The
single male with a PCDH19 deficiency was mosaic in his
skin; i.e., some of his cells express PCDH19 and others do
not. This finding suggests that a new pathogenic
mechanism—cellular interference—is associated with an
unusual X-linked mode of inheritance in which females are
more frequently affected than males.
PCDH19 Mutations in Dravet-Like Syndrome
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mutations.
The parents and relatives of PCDH19-positive patients were also
analysed when possible (Figure 3). The p.Glu48X mutation, found
in two affected sibs in family 2, was inherited from their
asymptomatic father. Likewise, the c.1036_1040dup5, p.As-
p121Asn and p.Leu543Pro mutations were inherited from the
healthy fathers of the index cases in families 6, 8 and 12. In family
6, the 5-bp duplication was inherited from the paternal
grandmother who also had epilepsy and cognitive impairment,
and transmitted to the half-brother of the father and his affected
daughter (i.e. the index case’s cousin, Figure 3). In family 4, the
mother of the proband had mental retardation associated with
adult-onset epilepsy, a clinical feature also present in the maternal
grandmother and maternal aunt; the proband’s father also
presented with moderate mental retardation but without epilepsy.
Figure 1. Identification of a deletion encompassing PCDH19 in a male patient. A) Identification of a hemizygous Xq22.1 deletion with a
370 K SNP microarray (Illumina): Y-axes represent Log R ratio (above) and B allele frequency (below); the X-axis indicates the position on the X
chromosome. The red line (log R ratio profile) corresponds to the median smoothing series (Beadstudio). B) Analysis of the patient and his mother
with CGH microarrays (Nimblegen), showing that the deletion occurred de novo. Indicated genomic positions are based upon the Ensembl Genome
Browser. Black horizontal bars (below) represent the gene (PCDH19) and pseudogenes comprised in the deleted region.
doi:10.1371/journal.pgen.1000381.g001
PCDH19 Mutations in Dravet-Like Syndrome
PLoS Genetics | www.plosgenetics.org 3 February 2009 | Volume 5 | Issue 2 | e1000381The Glu287X mutation in this family was also inherited from the
father. In contrast, in families 5, 7, 10 and 11, the mutations
(p.Glu287X, c.506delC and p.Asn340Ser, respectively) occurred
de novo in the index cases, since they were not found in either
parent. Interestingly, Arg1107Gly was inherited from the
asymptomatic father in family 5. In family 4, only the mother
and sisters of the index case were available for genetic analyses.
Both sisters, who were monozygous twins, had mild psychomotor
and cognitive impairment but never had seizures. Neither the
mother nor the sisters had the p.Glu287X mutation. Analysis of
the haplotypes in Xq22.1 (PCDH19 locus) with microsatellite
markers confirmed that the three sisters (the two twins and the
affected proband) received the same X chromosome from their
father, with and without the p.Glu287X mutation, which indicates
that the mutation also occurred de novo in this family. Finally, in
family 9, the mother did not have the p.Glu199Gln mutation but
the father remained unavailable for genetic analyses.
FISH Shows Somatic Mosaı ¨cism in the Male Patient with
the PCDH19 Deletion
Recently, PCDH19 mutations were shown to cause epilepsy and
mental retardation limited to females (EFMR), a familial disorder
associating childhood-onset epilepsy and a variable degree of
cognitive impairment with an unusual mode of inheritance: this X-
linked disorder is found in females with heterozygous mutations
but not in males with hemizygous mutations [6]. How, then, can
we explain the affected male in our series with a deletion of the
entire PCDH19? Random X-inactivation in mutated females
normally leads to tissue mosaicism in which two cell populations,
one expressing normal PCDH19 and the other expressing the
mutated allele, co-exist. To explain why only females are affected,
it might be hypothesized that the co-existence of PCDH19-positive
and PCDH19-negative cells would be pathogenic whereas
homogeneous cell populations (PCDH19-positive in normal
individuals but PCDH19-negative in mutated males) would not
[6]. A mechanism of this type was previously termed ‘‘cellular
interference’’ [21]. Two cell populations would also be found in
mosaic males, who, according to this hypothesis, would be affected
like mutated females.
To test whether our male patient was mosaic for the PCDH19
gene deletion, we compared peripheral blood lymphocytes (PBL)
and cultured fibroblasts from the patient by FISH with a probe
specific to the PCDH19 genomic region. Although no signal
corresponding to PCDH19 was detectable in PBL, a normal
PCDH19 allele was found in 53% of the fibroblasts (Figure 4),
confirming that the patient was mosaic, in his skin, for the
Figure 2. Detection of 9 different point mutations of PCDH19 in 11 female patients by direct sequencing. A) Sequence
electropherograms of the mutations and the missense variant (c.3319C.G/p.Arg1107Gly) identified in association with the c.859G.T/p.Glu287X
nonsense mutation. The mutation nomenclature is based on the PCDH19 transcript reference EF676096. Nucleotides are numbered according to the
cDNA with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to the journal guidelines (www.
hgvs.org/mutnomen). B) Alignment of the regions surrounding the mutations (indicated by an arrow) in orthologous and paralogous proteins,
showing the high conservation of each affected amino-acid in vertebrates and in the delta protocadherin paralogous genes.
doi:10.1371/journal.pgen.1000381.g002
PCDH19 Mutations in Dravet-Like Syndrome
PLoS Genetics | www.plosgenetics.org 4 February 2009 | Volume 5 | Issue 2 | e1000381PCDH19 deletion. This result confirms that mutations in PCDH19
can be responsible, in mosaic males, for epileptic encephalopathy
phenotypes that are usually limited to females, and strongly
supports the hypothesis that cellular interference is the main
pathogenic mechanism of the disease.
Clinical Features of the Patients with PCDH19 Mutations
or Deletions
The clinical features of the male patient with the PCDH19
deletion and the female patients with PCDH19 point mutations are
summarized in Table 1. These patients fulfil the main criteria for
Figure 3. Pedigrees of the families and segregation analysis of the PCDH19 deletion and point mutations. del/+,m / + or v/+ denote
individuals heterozygous for the deletion, mutation or variant, respectively; +/+ denotes individuals carrying homozygous wild-type alleles. Squares
represent males, circles females; filled black symbols: patients diagnosed as having Dravet syndrome; right black half: Cognitive delay or impairment;
left grey half: adolescence-onset idiopathic epilepsy. Dots in the middle of the squares indicate unaffected mutation carriers. The arrows indicate the
index cases.
doi:10.1371/journal.pgen.1000381.g003
PCDH19 Mutations in Dravet-Like Syndrome
PLoS Genetics | www.plosgenetics.org 5 February 2009 | Volume 5 | Issue 2 | e1000381DS (see material and methods’ section), with a mean age of
seizures onset of 9.5 months (ranging from 7.5 to 12 months).
Nevertheless, contrary to SCN1A-positive patients (SCN1A-DS),
myoclonic jerks, atypical absences, and photosensitivity were
unfrequent in PCDH19-positive patients (PCDH19-DS) (3, 3 and 1
patients out of 13, respectively). Only 6 patients presented status
epilepticus. The mental delay was mild in 6 patients, moderate in 4
and only 3 patients presented with severe delay. Although much
delayed, the language was present in all patients, with 12 out of 13
able to formulate short sentences.
Discussion
In this study, we used SNP microarrays to search for
microrearrangements in patients with clinical features suggestive
of Dravet syndrome but without mutations in SCN1A in order to
identify new causative genes. The identification of a de novo
hemizygous deletion of PCDH19, encoding protocadherin 19, in a
male patient led us to screen the coding region of this gene in the
remaining patients. Eleven unrelated probands with point
mutations in PCDH19, all females, were found. While this study
was ongoing, PCDH19 was reported to be the causative gene for
female-limited epilepsy and cognitive impairment (EFMR), a
disorder characterized by seizure onset in infancy or early
childhood and cognitive impairment, which is found only in
females in multi-generational families [6]. Since all of our patients
with point mutations in PCDH19 were females as previously
reported, we investigated the possibility that the male patient in
whom the gene was deleted might be mosaic for the deletion.
FISH analysis confirmed this latter hypothesis.
The thirteen patients with PCDH19 mutation or deletion (12
probands and one sib, family 2) all fulfilled the main criteria for DS
and were all negative for mutation or rearrangement in SCN1A after
direct sequencing and multiplex ligation-dependent probe amplifi-
cation (MLPA) [15]. The proportion of PCDH19-DS probands in
our series of SCN1A-negative patients was 16% (12/74), or even
25%(11/45)ifonlyfemalepatientswereincludedinthe calculation.
Considering that approximately 25% of all patients with DS are
SCN1A-negative [15], PCDH19 might overall account for 5% of DS
patients. PCDH19-DS patients and SCN1A-DS patients have
many features in common including: normal psychomotor
development before seizures onset, early onset of seizures (before
age one year), association of febrile and afebrile seizures, with a high
susceptibilityof the seizuresto feverforall13patients, occurrence of
hemiclonic or unilateral seizures (11/13), and association of
generalized tonic-clonic and focal seizures (12/13), a high
proportion of seizures occurring in clusters (12/13), prolonged
seizures, a proportion of which lead to status epilepticus, secondary
progressive appearance of mental and motor regression and
language delay, accompanied, in some cases, with ataxia (Table 1).
However, PCDH19-DS patients slightly differ on average from
the classical pattern reported in SCN1A-DS. PCDH19-DS
Figure 4. FISH analysis of the PCDH19 deletion in the male patient showing somatic mosaicism in fibroblasts. (A) Absence of the
specific Xq22.1 probe site on metaphase chromosomes in peripheral blood lymphocytes (PBL); (B) In fibroblasts, presence of one hybridization spot in
53% of the cells and absence of signal in the remaining 47%; C) and D) FISH analysis on PBL (C) and fibroblasts (D) of a female control. PCDH19-
specific signals (red) are indicated by arrowheads. Magnification 61000.
doi:10.1371/journal.pgen.1000381.g004
PCDH19 Mutations in Dravet-Like Syndrome
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months, with a range from 7.5 to 12 months, versus 6.3 months,
calculated from our series of SCN1A-positive DS patients,
p,0.0001) [15]. Less than half (6/13) of the PCDH19-DS
patients had status epilepticus although this is a highly frequent
feature in SCN1A-DS (93/113, p,0.007). Photosensitivity,
frequently reported in SCN1A-DS, was exceptional in
PCDH19-DS and was reported in only one patient but the
difference with SCN1A-DS in our series of patients was however
not significant. Seizures were, on average, less intractable than in
SCN1A-DS, and patients above six years of age (9/12 patients)
had less than 4 seizures a year with one patient who was free of
seizures at the time of the study. Although all patients were on tri-
or poly-therapy, seizures were relatively well-controlled, a situation
rarely achieved in SCN1A-DS. Intellectual and language delay
were constant but were less severe than the classical outcome of
SCN1A-DS [8] (mostly with important speech and mental delay)
although the difference was not significant. Finally, myoclonic
jerks and atypical absences were present in only 2 and 3 patients,
respectively, whereas they are frequent features in SCN1A-DS
(myoclonic jerks: 55/110, p,0.018; atypical absences: 92/108,
p,0.0001). Patients with SMEI but without myoclonia have been
previously referred as SMEB (borderline severe myoclonic epilepsy
in infancy) [22], but SMEI and SMEB are currently grouped
together under the term DS. In addition, the same types of
mutation, and even the same mutations, are found in patients with
DS and patients with other infantile epileptic encephalopathies
(such as cryptogenic generalized or focal epilepsies), which has
extended the clinical spectrum of SCN1A and the definition of DS
[15]. Therefore, in individuals, these divergent clinical character-
istics are not sufficient to distinguish between patients with SCN1A
or PCDH19 mutations, and the two clinical spectrums largely
overlap. They can be useful, however, to prioritize molecular
diagnosis although they must be first confirmed on larger series.
Mutations in PCDH19 were recently reported to cause EFMR,
which also associates mental retardation and epilepsy exclusively
in females. EFMR was differentiated from DS by the authors on
both clinical and genetic grounds [6,23]. The clinical features of
EFMR, unlike those of DS, are highly variable, even in members
of the same family: onset of seizures is between 6 and 36 months,
the patients present with a combination of febrile and afebrile
seizures of various types and a variable degree of psychomotor
delay and cognitive impairment, ranging from mild to severe
mental retardation [23]. Dibbens et al. reported PCDH19
mutations in six large families and one small family with two
affected sib pairs [6]. All the patients were familial cases that were,
for the most part, already adults at the time of examination, and
appeared socially integrated in that most of them were married
and had children. In the present study, on the contrary, the
patients were essentially young, had a severe epileptic encepha-
lopathy, and 8 of the 12 were isolated cases. In 6 patients out of 11
in whom inheritance could be assessed, the mutation occurred de
novo. In the 5 remaining patients, the mutation was inherited from
fathers who were healthy, had no cognitive impairment, and never
had febrile seizures or epilepsy (families 2, 6, 8 and 12), or had
mild mental retardation but no epilepsy (family 4). The global
clinical pictures of PCDH19-DS and EFMR appear therefore to
differ. The difference in the phenotypes might be due to the modes
of recruitment (familial versus sporadic cases). It might also be
hypothesized, that patients with PCDH19-DS have a better final
outcome than in those with SCN1A-DS despite the severity of
their disease in childhood and that the two disorders are different
clinical expressions of the same disease. Both hypotheses are not
mutually exclusive. Interestingly, the variability in the severity of
epilepsy and cognitive impairment in EFMR is reminiscent of
what is observed in GEFS+ families (generalized epilepsy with
febrile seizures plus, # MIM# 604233), an autosomal dominant
condition that also associates febrile seizures with epilepsy of
variable types and severity, and which is associated in ,10–15%
of the families with missense mutations in SCN1A [10]. Although
patients with GEFS+ are usually responsive to treatment and
generally have a benign outcome, some family members may be
more severely affected, and even present with DS. The clinical
spectrum of PCDH19 mutations could be as broad as the spectrum
of GEFS+. Random X inactivation could contribute to this
variability by generating variable proportions of mutated to
normal cells in the brains of the mutated females.
Although the mutations in EFMR families and in PCDH19-DS
patients are distinct, the spectra of mutations are comparable, and
include nonsense mutations, small deletions/insertions introducing
a frameshift as well as missense mutations affecting highly-
conserved amino-acids in the protein (Figure 5), which would
probably cause loss-of-function of the mutated allele. Messenger
RNAs with mutations introducing premature termination codons
(PTC) have indeed been shown to be degraded via the nonsense-
mediated mRNA decay (NMD) surveillance system of the cell in
fibroblasts from EFMR patients [6]. The identification of a whole
gene deletion in the mosaic male patient with PCDH19-DS also
supports the loss-of-function as the main consequence of the
mutations. However, all the point mutations identified so far are
clustered in the large exon 1 of the gene corresponding to the
extra-cellular cadherin domain of the protocadherin 19 protein, as
previously reported by Dibbens and collaborators [6]. Further
studies are needed to determine whether PTC mutations can be
found in other exons; this would be expected if the loss-of-function
assumption is correct.
EFMR and PCDH19-DS are paradoxical X-linked disorders in
which mutated females are severely affected whereas males
carrying the mutation are phenotypically unaffected: they have
normal cognitive function and no seizures although a subtle
psychiatric carrier status was evoked [6,23]. All affected patients
with point mutations identified in this study were also females. In
families 2, 4, 6, 8 and 12, the mutation was inherited from the
father. Five males (families 2, 6 and 8) were asymptomatic carriers
of PCDH19 mutations, they were healthy, had no cognitive
impairment or epilepsy, and none had histories of febrile seizures.
In family 4, however, the father who transmitted the mutation to
his daughter had moderate mental retardation but no epilepsy.
The link between the mutation and his cognitive impairment
remains, however, uncertain. The only definitely affected male
was, therefore, the patient who was mosaic for the PCDH19
deletion. There was no molecular evidence of mosaicism in the
blood of the father in family 4.
Several mechanisms have been suggested to account for the
unusual mode of inheritance observed in EFMR. 1) A dominant
negative effect of the mutant protein in females (as for mutations in
STK9/CDKL5 and MECP2) is unlikely, since it is usually associated
with lethality in males. 2) Compensatory factors may exist in
males; in particular, a protocadherin gene on the Y chromosome
(PCDH11Y) is specifically expressed in males and could play a role
in a sex-dependent compensation; a paralogous gene is located on
the X chromosome (PCDH11X), but the proteins encoded by the
two genes are not identical [6]. In addition, the protocadherin
family contains more than 80 genes scattered throughout the
human genome [24], supporting the hypothesis of molecular
compensation. 3) Another explanation for the unusual mode of
inheritance associated with PCDH19 mutations is cellular
interference, a mechanism reminiscent of metabolic interference
PCDH19 Mutations in Dravet-Like Syndrome
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chromosome in mutated females generates tissue mosaicism (i.e.
co-existence of PCDH19-positive or PCDH19-negative cells), which
would be pathogenic by altering cell-cell interactions; normal
individuals and mutated males, who are homogeneous for
PCDH19-positive or PCDH19-negative cells respectively, would
not develop the disease (Figure 6). The identification of an affected
male who was mosaic for the PCDH19 deletion in his fibroblasts,
and therefore had PCDH19-positive and PCDH19-negative cells in
this tissue, strongly supports the hypothesis of cellular interference
as the main pathogenic mechanism associated with PCDH19
mutations. The co-existence of normal and mutated cells and the
proportion of each population in the brain of this patient cannot,
however, be extrapolated from fibroblasts or lymphocytes. To
definitely establish that cellular interference is the pathogenic
mechanism, it is necessary i) to demonstrate that neuronal cells are
mosaic, but also that ii) females who are homozygous for PCDH19
mutations or deletions are also unaffected, like hemizygous males.
Although pathogenesis in cells that express the mutated allele after
inactivation corresponds to a loss-of-function, cellular interference
would result in a gain-of-function at the tissue level, because of
abnormal interactions between mutated and normal cells. This
hypothesis supposes that the loss of protocadherin 19 is
compensated for, but by a mechanism that is relatively
independent of gender.
The same X-linked pattern of inheritance and has been
observed for craniofrontonasal syndrome (CFNS), a disorder in
which females have multiple skeletal malformations. The gene
responsible for CFNS is EFNB1, located in Xq12 and encoding
Ephrin B1, a transmembrane protein that is a ligand for Eph
receptors [21]. The Ephrin B1/Eph interaction plays a role in cell
migration and pattern formation during developmental morpho-
genesis [26]. Cellular interference, also proposed as the pathogenic
mechanism for CFNS [21], had previously been demonstrated in
female mice heterozygous for Ephrin B [27]. Although homozy-
gous female and hemizygous male mice showed comparable
perinatal lethality due to major skeletal abnormalities, heterozy-
gous females were even more affected, and they alone had
polydactyly. Ephrin B1-EphB receptor signaling was shown to
regulate skeletal development by controlling cell movement.
Mosaic expression of Ephrin B1, caused by random X inactivation
in heterozygous females, results in ectopic interactions between the
Ephrin B1 ligand and EphB receptors, sufficient to induce the
skeletal defects [27].
Protocadherin 19 is an 1148 amino-acids transmembrane
protein belonging to the protocadherin delta2 subclass of the
cadherin superfamily, which is highly expressed in neural tissues
and at different developmental stages [6,28,29]. The precise
functions of the protein remain so far unknown. However, Delta
protocadherins were reported to mediate cell-cell adhesion in vitro
and cell sorting in vivo, and could regulate the establishment of
neuronal connections during brain development [24,30]. Ephrin
B1 and protocadherin 19 could therefore share major character-
istics. Several isoforms of protocadherin 19 have been reported to
result from alternative splicing of exon 2 and the existence of two
acceptor sites for intron 4 which adds a residue at the beginning of
exon 5. The isoform(s) implicated in the physiopathology of
EFMR and PCDH19-DS are still not known. Functional studies as
well as the development of mouse models are now needed to
confirm and unravel the molecular mechanisms of cellular
interference in these diseases.
In conclusion, these results extend the clinical spectrum
associated with PCDH19 mutations: we demonstrated that
mutations in this gene are not limited to familial female patients,
but can also account for isolated cases. Our results suggest that
isolated mosaic male patients are also susceptible to the disease.
Finally, mutations in PCDH19 can cause an early and severe
epileptic encephalopathy mimicking DS, a major problem for
differential diagnosis. The high frequency of patients with
PCDH19 found in this study justifies the molecular testing of this
Figure 5. Schematic representation of the point mutations identified in the PCDH19 gene. Above: mutations identified in this study;
Below: mutations identified by Dibbens et al. (2008). SP: signal peptide; EC: extracellular cadherin domain; TM: transmembrane domain; CM1 and
CM2: cytoplasmic domains 1 and 2.
doi:10.1371/journal.pgen.1000381.g005
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having Dravet syndrome. This study also validates the use of SNP
microarrays to identify novel genes in isolated patients with severe
genetic pathologies. This strategy will hopefully identify new
genomic regions or genes that would account for the ,15–20% of
DS patients that do not have SCN1A and PCDH19 mutations.
Materials and Methods
Patients
A total of in 74 probands (45 females and 29 males), referred by
specialized neuropediatric centres as having Dravet syndrome but
who were negative for point mutations or rearrangements in
SCN1A, were included in the study [15]. Forty-one of these patients
were initially selected for the microarray analysis and 33 were later
on included for sequencing of PCDH19. The referring physicians
filled out detailed clinical questionnaires for every patient. Clinical
histories were also obtained when possible to assess the evolution of
thedisease.Allclinicalreports and questionnaireswerere-examined
by the same neuropediatrician (RN). Intellectual assessment was
based on psychological evaluation when available. Psychomotor
skills and cognitive delay were clinically evaluated in all patients.
The clinical diagnosis of DS included: normal cognitive and motor
development prior to seizures onset, onset of the seizures before the
age of one year, seizures mainly triggered by fever, long-lasting
seizures (.15 min, that might evolve to status epilepticus), later
occurrence of other types of seizures (febrile and afebrile) and
cognitive regression. The presence of myoclonic jerks and/or ataxia
was considered to be a highly characteristic, although inconstant,
feature of the diseasethat could reinforce a diagnosis; however, their
absence did not exclude the clinical diagnosis of Dravet syndrome,
since they were not previously observed in all patients with DS
[7,31]. Informed written consent was obtained from the patients’
parents before blood sampling. This study was approved by the
ethical committee (CCPPRB of Pitie ´-Salpe ˆtrie `re Hospital, Paris,
nu69-03, 25/9/2003).
Screening for Genomic Rearrangements with High-
Density SNP Arrays
Patients were screened using Illumina 370CNV-Duo genotyp-
ing BeadChip arrays (370 K). The Infinium II Genotyping
reaction steps were performed according to the manufacturer’s
specifications (Illumina, San Diego, CA) on the P3S platform
(Pitie ´-Salpe ˆtrie `re Hospital). Briefly, 750 ng of genomic DNA were
isothermally amplified at 37uC overnight. The amplified products
were fragmented by a controlled enzymatic process then
precipitated with isopropanol. The dried precipitated pellet was
resuspended, hybridized to 370CNV-Duo beadchips in a capillary
flow-through chamber and incubated overnight at 48uC. The
amplified, fragmented DNA samples anneal to locus-specific 50-
mers during the hybridization step. Each bead type corresponds to
one allele per SNP locus. After hybridization, allelic specificity was
conferred by enzymatic single-base extension and fluorescent
staining. Arrays were washed and dried for 1 h before imaging
using a BeadArray Reader (Illumina). Image data analysis and
automated genotype calling was performed using Beadstudio 3.1
(Illumina). All genomic positions were based on the UCSC and
Ensembl Genome Browsers. Each copy number variant (CNV)
identified in patients was searched in the database of genomic
variants (http://projects.tcag.ca/variation/), which repertories the
structural variation in the Human genome, to determine whether
this CNV is normally present in a control population.
Analysis of the Xq22.1 Deletion with Nimblegen CGH
Arrays
Genomic DNA from the patients was analysed by microarray-
based comparative genomic hybridization with the HG18 WG
Figure 6. Schematic illustration of the cellular interference mechanism associated with PCDH19 mutations. A) In normal individuals,
characterized by a homogeneous population of PCDH19-positive cells, neurons are able to form normal neuronal networks; B) In mutated male
patients, hemizygosity leads to a homogeneous population of PCDH19-negative cells; in this condition, neurons preserve the ability to form normal
neuronal networks; C) In heterozygous mutated females, random X inactivation leads to the co-existence of two PCDH19-positive and PCDH19-
negative cell populations. These two cell populations cause divergent cell sorting and migration (due to attractive or repulsive interactions) and lead
to abnormal neuronal networks. Somatic mosaicism in mutated males gives rise to the same pathological situation. The precise mechanisms by
which the neuronal networks are altered are still unknown.
doi:10.1371/journal.pgen.1000381.g006
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according to the NimbleGen hybridization Kit Protocol. Briefly,
DNA samples from patients and controls were labelled by random
priming: the DNA (1 mg) was denatured in the presence of 59Cy3-
or Cy5-labeled random nanomers (Trilink Biotehcnologies, San
Diego, CA) and incubated with 100 units of exo-klenow fragment
(NEB, Beverly, MA) and dNTP mix [6 mM each in TE buffer
(10 mMTris/1 mM EDTA, pH 7.4, Invitrogen)] for 2 h at 37uC.
Reactions were terminated by addition of 0.5 mM EDTA
(pH 8.0), precipitated with isopropanol and resuspended in water.
The Cy-labelled test sample (Cy3) and the reference sample (Cy5)
were combined in 13 mL of Nimblegen Hybridization solution
(Roche Nimblegen). After denaturation, hybridization was carried
out on a MAUI Hybridization System (BioMicro Systems, Salt
Lake City, NE) for 18 h at 42uC. The array was washed with the
NimbleGen Wash System (Roche NimbleGen), dried by centri-
fugation and scanned with the genePix 4000B scanner (Axon
Instrument, Union City, CA). Fluorescence intensity (raw data)
was obtained from the scanned images of the oligonucleotide tiling
arrays with NIMBLESCAN 2.0 extraction software (Nimblegen
Systems). For each spot on the array, log2 ratios of the Cy3-labeled
test sample versus Cy5 reference sample were calculated. Regions
were considered to be duplicated or deleted when result exceeded
the +/20.25.
Sequencing of the PCDH19 Coding Sequence
Eleven specific primer pairs were designed to amplify the 6
exons and adjacent intron-exon boundaries (,100 bp from each
side of the exons) of the PCDH19 gene (transcript reference
EF676096). Primer sequences are available on request. Forward
and reverse sequence reactions were performed with the Big Dye
Terminator Cycle Sequencing Ready Reaction Kit (PE Applied
Biosystems) using the same primers. G50-purified sequence
products were run on an ABI 3730 automated sequencer (PE
Applied Biosystems) and data were analyzed with the Seqscape 2.5
software (Applied Biosystems). Mutations identified in the patients
were looked for directly in the DNA of available parents by
sequencing the corresponding amplicon. If neither parent had the
mutation, the parents were tested with microsatellite markers at
the Xq22.1 locus to ensure that the mutation occurred de novo. In
addition, 180 European controls (90 males and 90 females) were
included to test new variants in the PCDH19 gene.
Fluorescence In Situ Hybridization (FISH)
FISH experiments were performed on peripheral blood
lymphocytes (blood samples) and fibroblasts (skin biopsies).
Fibroblasts were grown in Dulbecco’s modified Eagle’s medium
containing 4.5 mg/ml glucose and 110 mg/ml pyruvate (DMEM)
supplemented with 10% fetal calf serum (FCS), 0.03% glutamine,
1000 U/ml penicillin/streptomycin in a 5% CO2 atmosphere for
2 weeks before FISH. Lymphocytes were grown in PB-Max
medium (Invitrogen) for 3 days. Metaphase chromosome spreads
were obtained by standard hypotonic treatment and methanol/
acetate (3/1) fixation. The slides were washed with the cytology
FISH accessory kit (Dako). A FISH DNA probe, specific for the
Xq22.1 region covering PCDH19, was labeled with rhodamine by
nick-translation after amplification of the RP11-99E24 BAC
(Invitrogen) and cohybridized with a commercial subtelomeric
control probe (Cytocell), specific for the pseudo-autosomal region
1 (chromosomes X/Y) labeled with fluorescein isothiocyanate
(FITC). The slides were then washed and counterstained with 4,6-
diamino-2-phenylindole (DAPI) for chromosome identification.
Metaphase cells were examined under a motorized reflected BX61
Olympus fluorescence microscope with filters for separate
detection of DAPI, FITC and rhodamine. One hundred
metaphase cells were counted to determine the degree of
mosaicism in fibroblasts and lymphocytes. Metaphase chromo-
somes from a karyotypically normal female were used as a control.
Statistical Tests
Frequencies were compared with the Chi-Square test or the
Fisher exact test when appropriate. Means were compared using
Mann-Whitney Rank Sum Test. Statistical analysis was performed
using SigmaStat 3.5 software.
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